Multiple sclerosis (MS) is a chronic autoimmune disease where the body’s immune system mistakenly attacks the central nervous system. For patients, this often means years of relapsing symptoms, neurological decline, and a lifelong dependence on disease-modifying therapies (DMTs). While drugs like glatiramer acetate (GA), interferon-β (IFNβ), and fingolimod help dampen inflammation, doctors still face a critical challenge: predicting who will respond well to treatment.

A team led by Chiara Cordiglieri and Renato Mantegazza at the Neurological Institute “Carlo Besta” in Milan tackled this head-on. Their 2016 study, published in Clinical Immunology, sought to identify biomarkers in blood that could reveal how MS patients respond to therapy.

Why Biomarkers Matter in MS
Right now, MS diagnosis and monitoring largely depend on clinical symptoms and MRI scans. Blood tests that could predict treatment response are essentially missing. For a disease that varies so much from person to person, having molecular “signatures” in blood would be a game changer.

This study asked: Can we detect consistent gene expression changes in the blood of MS patients who respond to therapy?

The Study Design in a Nutshell
Participants: 78 patients with relapsing-remitting MS (RR-MS) and 47 healthy donors.

Approach: Researchers used whole-blood RNA microarrays, followed by validation with qPCR and protein analysis.

Phases:

Discovery: Initial screen in GA-treated patients.

Validation: Confirm findings in new groups.

Longitudinal follow-up: Track changes over 12 months in patients on GA, IFNβ, or fingolimod.

The “Magic Eight”: A Gene Signature Emerges
The researchers zeroed in on eight genes that showed striking changes with treatment:

Downregulated with therapy:

ITGA2B, ITGB3 (integrin subunits)

CD177 (cell adhesion molecule)

IGJ (immunoglobulin J chain)

IL5RA (IL-5 receptor alpha)

MMP8 (matrix metalloproteinase)

P2RY12 (purinergic receptor)

Upregulated with therapy:

S100β (a calcium-binding protein, often linked to brain damage but here upregulated in blood cells during therapy).

Interestingly, while most genes were suppressed by treatment, S100β consistently went up across all therapies.

What Do These Genes Tell Us?
These aren’t random players—many are tied to immune cell trafficking, adhesion, and inflammation, all central in MS pathology:

Integrins (ITGA2B/ITGB3) and CD177 help immune cells cross the blood-brain barrier. Their downregulation suggests therapies reduce harmful infiltration into the CNS.

MMP8, an enzyme that remodels extracellular matrix, is known to aid immune cell migration. Lower levels could mean reduced tissue damage.

P2RY12 and IL5RA are involved in immune signaling, with P2RY12 also linked to neuron-glia communication.

S100β, usually a marker of CNS injury, appeared in peripheral immune cells. Its increase in regulatory T-cells, B-cells, and NK cells hints at a protective or regulatory role under therapy.

Therapy-Specific Twists
Although the general pattern held across GA, IFNβ, and fingolimod, there were drug-specific nuances:

GA uniquely decreased MMP8.

IFNβ did not affect IL5RA.

Fingolimod had distinct effects on CD8+ T cells, boosting S100β in these populations.

This suggests that while the therapies differ mechanistically, they converge on shared immune pathways.

Why This Matters for MS Patients
If validated in larger cohorts, this 8-gene signature could serve as a peripheral blood biomarker panel to:

Monitor therapy effectiveness.

Tailor treatments to individual patients.

Provide molecular insight into how different drugs exert their effects.

In a field hungry for precision medicine, these findings offer a promising step toward personalized MS care.

Takeaway
The Milan team’s work gives us a hopeful glimpse into the future: blood-based gene signatures that mirror how MS patients respond to treatment. Beyond guiding therapy, the study also sheds light on the shared biology of DMTs—reducing harmful immune cell trafficking while promoting regulatory immune populations.

Disclaimer: This blog post is based on the information provided in the cited scientific article. It aims to provide an accessible summary of the research findings and should not be considered as definitive medical advice. For any health concerns, please consult with a qualified healthcare professional.

Reference:
Cordiglieri, C., Baggi, F., Bernasconi, P., Kapetis, D., Faggiani, E., Consonni, A., ... & Mantegazza, R. (2016). Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. Clinical Immunology, 173, 133-146.